BPC-157 Legal Status, FDA 503A Category, and Compounding Access

Access Is Under Active FDA Review and May Expand in 2026

BPC-157 legal status is in motion. BPC-157 is individually named on the published agenda of the FDA Pharmacy Compounding Advisory Committee (PCAC) meeting scheduled for July 23-24, 2026, as a bulk drug substance 'being considered for inclusion on the 503A Bulks List' ^[17]. The same agenda also lists KPV, TB-500, and MOTs-C ^[17]. That is real, forward momentum: a substance FDA has explicitly placed on a committee agenda for evaluation, not one sitting untouched.

The boundaries matter, and this digest states them precisely. A PCAC discussion is a scheduled evaluation and an advisory step — it is not a listing decision, not a reclassification, and not a change in BPC-157's current status ^[17]. Inclusion on a final 503A bulks list is decided by FDA rulemaking informed by the committee, and being discussed by PCAC is a step in evaluation rather than an outcome ^[18]. The momentum is genuine; the conclusion is not yet written, and this page will not pretend otherwise by attaching an outcome or a date to a meeting that has only been scheduled.

The Current Fact: FDA 503A Category 2

As of the latest FDA action confirmable from FDA.gov, BPC-157 sits in 503A Category 2. FDA identified BPC-157 — evaluated under the list entries 'BPC-157 (free base)' and 'BPC-157 acetate' — as a bulk drug substance that may present significant safety risks and placed it in Category 2 for 503A compounding, effective with FDA's September 29, 2023 update to the nominated-substances list ^[16]. FDA's stated concerns include potential immunogenicity for certain routes of administration and complexities with peptide-related impurities and active-ingredient characterization ^[16].

Two consequences follow directly. Because Category 2 substances are those FDA has identified as raising significant safety risks, BPC-157 is not within FDA's enforcement-discretion policy for 503A compounding while that status stands ^[18]. And separately, BPC-157 is not an FDA-approved drug — there is no approved finished-drug application for it, which is a distinct question from the compounding-eligibility one ^[16]. This is the REGULATORY-graded core of the page: the present-tense, FDA-citable status, stated without spin.

One further status belongs on the record for athletes. BPC-157 is prohibited in sport at all times by the World Anti-Doping Agency, which places non-approved substances of this kind in its S0 category. That prohibition is independent of the FDA compounding question — a substance can be ineligible for routine 503A compounding and separately banned in competition — and both facts coexist in BPC-157's current standing.

What 503A Category 2 Means

U.S. drug compounding runs through two sections of the Federal Food, Drug, and Cosmetic Act. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies and physicians, generally pursuant to a valid prescription for an individual patient; Section 503B covers FDA-registered outsourcing facilities that compound larger batches under cGMP-style oversight ^[18]. A compounder may use a bulk drug substance only if it has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on the relevant FDA bulks list; otherwise it is evaluated by FDA through a public nomination process with input from PCAC ^[18].

Within that framework, FDA's interim policy sorted nominated substances into categories. Category 1 substances may be eligible for the bulks list and are covered by FDA's enforcement-discretion policy while under evaluation; Category 2 substances are those FDA identified as raising significant safety risks and are not afforded that discretion ^[18]. BPC-157 is in Category 2 ^[16]. On January 7, 2025, FDA finalized a revised interim policy under which it no longer places newly nominated substances into these numbered categories, while stating that substances already in Category 2 are not afforded enforcement discretion even if nominations are updated ^[18][19]. So BPC-157's FDA 503A compounding status is governed by where it already stood — in Category 2 — rather than by the change in how new nominations are handled.

How Legally Compounded Peptide Access Works

In general terms, a legally compounded medication is prepared only after an individual patient is evaluated by an appropriately licensed prescriber who determines a compounded preparation is clinically appropriate and issues a valid, patient-specific prescription ^[18]. The preparation is then made by a state-licensed 503A compounding pharmacy (patient-specific) or, for larger volumes, sourced from an FDA-registered 503B outsourcing facility ^[18]. Telehealth can serve as the front-end channel through which the prescriber evaluation and prescription happen, but it does not change which substances are eligible to be compounded and does not remove the need for a legitimate prescriber-patient relationship and a valid prescription ^[18].

The ingredient-eligibility caveat is the binding one. A compounder may use a requested active ingredient only if that ingredient is eligible under the 503A and 503B bulk-substance rules; ingredients FDA has flagged for significant safety risks are not eligible for routine 503A compounding while that status stands ^[18]. For BPC-157, that means its Category 2 designation is the gating fact today ^[16] — and the scheduled July 2026 PCAC evaluation is the process that may, or may not, change it ^[17]. This page is general information about the regulatory landscape, not medical or legal advice, and not an offer to sell or supply any substance. It names no pharmacy, clinic, telehealth provider, or vendor, and it provides no dosing.

For the underlying findings this access framework governs, see the BPC-157 research findings and the BPC-157 angiogenesis research pages.